Original Source(s)
Related Content
FDA Approves New First-Line TNBC Regimen
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
June 26, 2026
-
3 min
Top 10 CDC Updates Physicians Should Know
Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.
July 9, 2026
-
6 min